Literature DB >> 21525397

The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics.

Ruili Huang1, Noel Southall, Yuhong Wang, Adam Yasgar, Paul Shinn, Ajit Jadhav, Dac-Trung Nguyen, Christopher P Austin.   

Abstract

Small-molecule compounds approved for use as drugs may be "repurposed" for new indications and studied to determine the mechanisms of their beneficial and adverse effects. A comprehensive collection of all small-molecule drugs approved for human use would be invaluable for systematic repurposing across human diseases, particularly for rare and neglected diseases, for which the cost and time required for development of a new chemical entity are often prohibitive. Previous efforts to build such a comprehensive collection have been limited by the complexities, redundancies, and semantic inconsistencies of drug naming within and among regulatory agencies worldwide; a lack of clear conceptualization of what constitutes a drug; and a lack of access to physical samples. We report here the creation of a definitive, complete, and nonredundant list of all approved molecular entities as a freely available electronic resource and a physical collection of small molecules amenable to high-throughput screening.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21525397      PMCID: PMC3098042          DOI: 10.1126/scitranslmed.3001862

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  33 in total

1.  Drug withdrawals from the Canadian market for safety reasons, 1963-2004.

Authors:  Joel Lexchin
Journal:  CMAJ       Date:  2005-03-15       Impact factor: 8.262

Review 2.  Screening existing drugs for neurodegeneration: The National Institute of Neurologic Disorders and Stroke (NINDS) model.

Authors:  Jill Heemskerk
Journal:  Retina       Date:  2005-12       Impact factor: 4.256

3.  Is pregabalin a safe and effective treatment for patients with fibromyalgia?

Authors:  Michael Spaeth
Journal:  Nat Clin Pract Rheumatol       Date:  2008-09-02

Review 4.  Thalidomide: a remarkable comeback.

Authors:  J M Jacobson
Journal:  Expert Opin Pharmacother       Date:  2000-05       Impact factor: 3.889

5.  Identification of a primary target of thalidomide teratogenicity.

Authors:  Takumi Ito; Hideki Ando; Takayuki Suzuki; Toshihiko Ogura; Kentaro Hotta; Yoshimasa Imamura; Yuki Yamaguchi; Hiroshi Handa
Journal:  Science       Date:  2010-03-12       Impact factor: 47.728

6.  Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression.

Authors:  Jeffrey D Rothstein; Sarjubhai Patel; Melissa R Regan; Christine Haenggeli; Yanhua H Huang; Dwight E Bergles; Lin Jin; Margaret Dykes Hoberg; Svetlana Vidensky; Dorothy S Chung; Shuy Vang Toan; Lucie I Bruijn; Zao-Zhong Su; Pankaj Gupta; Paul B Fisher
Journal:  Nature       Date:  2005-01-06       Impact factor: 49.962

7.  Toxicity testing in the 21st century: implications for human health risk assessment.

Authors:  Robert J Kavlock; Christopher P Austin; Raymond R Tice
Journal:  Risk Anal       Date:  2008-12-09       Impact factor: 4.000

Review 8.  The pilot phase of the NIH Chemical Genomics Center.

Authors:  Craig J Thomas; Douglas S Auld; Ruili Huang; Wenwei Huang; Ajit Jadhav; Ronald L Johnson; William Leister; David J Maloney; Juan J Marugan; Sam Michael; Anton Simeonov; Noel Southall; Menghang Xia; Wei Zheng; James Inglese; Christopher P Austin
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

Review 9.  Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond.

Authors:  Hossein A Ghofrani; Ian H Osterloh; Friedrich Grimminger
Journal:  Nat Rev Drug Discov       Date:  2006-08       Impact factor: 84.694

10.  DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Authors:  David S Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali
Journal:  Nucleic Acids Res       Date:  2007-11-29       Impact factor: 16.971

View more
  187 in total

1.  Quantitative high-throughput drug screening identifies novel classes of drugs with anticancer activity in thyroid cancer cells: opportunities for repurposing.

Authors:  Lisa Zhang; Mei He; Yaqin Zhang; Naris Nilubol; Min Shen; Electron Kebebew
Journal:  J Clin Endocrinol Metab       Date:  2011-12-14       Impact factor: 5.958

2.  Identifying mechanism-of-action targets for drugs and probes.

Authors:  Elisabet Gregori-Puigjané; Vincent Setola; Jérôme Hert; Brenda A Crews; John J Irwin; Eugen Lounkine; Lawrence Marnett; Bryan L Roth; Brian K Shoichet
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-18       Impact factor: 11.205

3.  Structure based model for the prediction of phospholipidosis induction potential of small molecules.

Authors:  Hongmao Sun; Sampada Shahane; Menghang Xia; Christopher P Austin; Ruili Huang
Journal:  J Chem Inf Model       Date:  2012-07-05       Impact factor: 4.956

Review 4.  Computational and Practical Aspects of Drug Repositioning.

Authors:  Tudor I Oprea; John P Overington
Journal:  Assay Drug Dev Technol       Date:  2015 Jul-Aug       Impact factor: 1.738

5.  Assessment of the DNA damaging potential of environmental chemicals using a quantitative high-throughput screening approach to measure p53 activation.

Authors:  Kristine L Witt; Jui-Hua Hsieh; Stephanie L Smith-Roe; Menghang Xia; Ruili Huang; Jinghua Zhao; Scott S Auerbach; Junguk Hur; Raymond R Tice
Journal:  Environ Mol Mutagen       Date:  2017-07-17       Impact factor: 3.216

6.  Identification of drug modulators targeting gene-dosage disease CMT1A.

Authors:  Sung-Wook Jang; Camila Lopez-Anido; Ryan MacArthur; John Svaren; James Inglese
Journal:  ACS Chem Biol       Date:  2012-05-02       Impact factor: 5.100

7.  δ-Tocopherol reduces lipid accumulation in Niemann-Pick type C1 and Wolman cholesterol storage disorders.

Authors:  Miao Xu; Ke Liu; Manju Swaroop; Forbes D Porter; Rohini Sidhu; Sally Firnkes; Sally Finkes; Daniel S Ory; Juan J Marugan; Jingbo Xiao; Noel Southall; William J Pavan; Cristin Davidson; Steven U Walkley; Alan T Remaley; Ulrich Baxa; Wei Sun; John C McKew; Christopher P Austin; Wei Zheng
Journal:  J Biol Chem       Date:  2012-10-03       Impact factor: 5.157

8.  Identification of Nitazoxanide as a Group I Metabotropic Glutamate Receptor Negative Modulator for the Treatment of Neuropathic Pain: An In Silico Drug Repositioning Study.

Authors:  Ni Ai; Richard D Wood; William J Welsh
Journal:  Pharm Res       Date:  2015-03-12       Impact factor: 4.200

9.  Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen.

Authors:  Miao Xu; Emily M Lee; Zhexing Wen; Yichen Cheng; Wei-Kai Huang; Xuyu Qian; Julia Tcw; Jennifer Kouznetsova; Sarah C Ogden; Christy Hammack; Fadi Jacob; Ha Nam Nguyen; Misha Itkin; Catherine Hanna; Paul Shinn; Chase Allen; Samuel G Michael; Anton Simeonov; Wenwei Huang; Kimberly M Christian; Alison Goate; Kristen J Brennand; Ruili Huang; Menghang Xia; Guo-Li Ming; Wei Zheng; Hongjun Song; Hengli Tang
Journal:  Nat Med       Date:  2016-08-29       Impact factor: 53.440

10.  Glypican-3-Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma.

Authors:  Ying Fu; Daniel J Urban; Roger R Nani; Yi-Fan Zhang; Nan Li; Haiying Fu; Hamzah Shah; Alexander P Gorka; Rajarshi Guha; Lu Chen; Matthew D Hall; Martin J Schnermann; Mitchell Ho
Journal:  Hepatology       Date:  2019-02-19       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.